Narrative Review of Management Strategies and Risk Mitigation for Gastrointestinal Bleeding in Atrial Fibrillation Patients Receiving Warfarin

Le résumé fourni par la source

A globally prevalent cardiac arrhythmia, atrial fibrillation (AF) greatly increases the risk of thromboembolic events, making effective anticoagulation necessary. The mainstay of this treatment has long been the vitamin K antagonist warfarin. However, there are significant management challenges due to its limited therapeutic index, intricate pharmacokinetics, and multiple interactions, with gastrointestinal bleeding (GIB) emerging as a serious and potentially fatal complication. The epidemiology, risk factors, mechanisms, and management approaches for GIB in AF patients taking warfarin are summarized in this review. It emphasizes how crucial it is to conduct individualized risk assessments using validated scores, monitor anticoagulation closely, and strategically combine advanced endoscopic procedures with direct oral anticoagulants (DOACs). Increased monitoring and patient education are necessary because of the high early incidence of GIB and the inherent lability of warfarin's anticoagulant effect. Furthermore, accurate clinical differentiation is necessary due to the complex risk profiles of different medications, such as fibrates versus statins. The report highlights the need for a multidisciplinary approach to care, especially in complex situations such as the resumption of post-GIB anticoagulation. It also identifies new endoscopic tools, pharmacogenomics, and artificial intelligence as promising directions for future developments in safer and more individualized patient outcomes.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.